Oyster_Point_Social.jpg
Oyster Point Pharma to Present at the Cowen 40th Annual Healthcare Conference
February 24, 2020 08:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
February 24, 2020 08:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Disease
January 12, 2020 20:00 ET | Oyster Point Pharma, Inc.
OC-01 nasal spray showed a statistically significant improvement in Schirmer’s score at Day 84 in both doses tested compared to control  OC-01 nasal spray is a preservative-free, aqueous, nicotinic...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces Addition to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes
December 23, 2019 09:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma to Present at the 38th Annual J.P. Morgan Healthcare Conference
December 17, 2019 08:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights
December 03, 2019 07:00 ET | Oyster Point Pharma, Inc.
ZEN Phase 1 top-line data Closed IPO financing and received $92.0 million in gross proceeds PRINCETON, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a...
Oyster_Point_Social.jpg
Oyster Point Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference
November 25, 2019 08:00 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces Positive Top-Line Results From the Phase 1 “ZEN” Study of Its Lead Nicotinic Agonist Nasal Spray in Development for the Treatment of Dry Eye Disease
November 22, 2019 17:12 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
OFFICIAL LOGO OP horiz_color_marily
Oyster Point Pharma Announces Closing of Initial Public Offering
November 05, 2019 09:10 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class...
OFFICIAL LOGO OP horiz_color_marily
Oyster Point Pharma Announces Pricing of Initial Public Offering
October 30, 2019 20:17 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class...